Niarmedic
Russia
Central Federal District of the Russian Federation
Moscow
Aircraft designer Mikoyan, 12
Top managers:
Sergey Igorevich Arabadzhyan
Content |
NIARMEDIK is a Russian medical, innovative, biotechnology and pharmaceutical company. The main task of the office is to coordinate and manage the work of all clinics and warehouses that are part of the NIARMEDIC network.
Limited Liability Company "NIARMEDIC PLUS" - Russian pharmaceutical, biotechnological, medical company was created in 1989 by like-minded scientists of the Research Institute of Epidemiology and Microbiology named after N.F. Gamalei to introduce the results of his own scientific research and development into wide medical practice in various fields of laboratory diagnostics, immunology, infectology and other areas. The company produces diagnostic test systems, original pharmaceuticals, including the antiviral drug KAGOCEL and the COLLOST reducing complex. It supplies laboratory equipment manufactured by the world's leading manufacturers to the domestic market, conducts its service, and also develops a network of multidisciplinary clinics for the provision of comprehensive medical care. Today, NIARMEDIC PLUS is one of the TOP-10 of the best innovative companies in Russia that actively use biotechnology in medicine. General Director and Founder of the company, Doctor of Medical Sciences, Professor Vladimir Nesterenko.
History
2025: Appointment as CEO of Sergei Arabadzhyan
In early February 2025 "Niarmedic" , a new general director was appointed in the network of clinics. This position was taken by Sergei Arabadzhyan, who had previously worked in the company as deputy head for development. More here
2021: New Investment Holding JSC bought Niarmedic for 5.9 billion rubles
On September 15, 2021, the sale of Niarmedic to AFK Sistema and Sberbank for 1 ruble was announced. The symbolic value of the transaction is due to the large debts of the pharmaceutical company - about 5.9 billion rubles.
Under the terms of the agreement, New Investment Holding JSC, owned by AFK Sistema and Sberbank, bought Nearmedic International Limited, which owns 100% of the authorized capital of Niarmedic Plus LLC, Niarmedic Pharma LLC and other companies operating in the fields of pharmaceuticals, biotechnology and medicine.
The agreement provides that AFK Sistema can buy a share of Sberbank and obtain the rights of the bank's claim on the loan, which was provided to Niarmedic, in the amount of up to 2.8 billion rubles. The maximum term of execution of the agreement is 3.5 years from the date of closing of the transaction.
AFK Sistema President Vladimir Chirakhov, commenting on the deal, noted that Niarmedic has a development potential that can be implemented through restructuring and increased efficiency.
 | It is in this that AFK Sistema, as an investment company, has a powerful and proven expertise. Moreover, AFK Sistema has accumulated significant competencies in pharmaceuticals, medicine and biotechnology - all these areas are key for Niarmedic, he said, adding that in the near future it is planned to implement a plan to optimize Niarmedic's business, which is expected to increase the shareholder value of assets acquired under the transaction, and expand the production capabilities of Sistema. |  |
By mid-September 2021, the Niarmedic group includes production sites in Obninsk and Mosalsk, a medical device factory in Italy and a network of medical clinics in Moscow, Obninsk and Ryazan.[1]
2020
Association with the Center for Endosurgery and Lithotripsy
At the end of December 2020, it became known about the joining of the Center for Endosurgery and Lithotripsy (CELT) to the network of Niarmedic clinics, which, along with the Doctor Nearby network, is part of the joint Doctor Nearby Holding LLC. The financial component of the transaction was not disclosed. Read more here.
Creation of the company as a result of the merger of the Doctor Nearby and Niarmedic networks
In mid-July 2020, the Doctor Nearby and Niarmedic clinics completed the merger, which was announced a year earlier. As a result of the transaction, the shares of the combined company - United Company Niarmedic - Doctor Nearby LLC - were distributed between the shareholders of Doctor Nearby and Niarmedic in a ratio of 45% to 55%, respectively. Read more here.
2013
RUSNANO announced in December 2013 the successful withdrawal from the capital of NIARMEDIC PHARMA, a joint venture between RUSNANO and the Russian pharmaceutical company NIARMEDIC PLUS. RUSNANO's share in the authorized capital of the project company - 34.45% - was bought out for 2.3 billion rubles by the project applicant, NIARMEDIC PLUS LLC. RUSNANO's investment return (IRR) will be 41.1%.
RUSNANO investments in the amount of 1.3 billion rubles were primarily directed to the construction of the company's plant in the city of Obninsk, Kaluga Region. The total area of the complex, the commissioning of which is fully scheduled for 2014, will be 22 thousand square meters. The general contractor was FormaPharm Engineering Group, which has experience in the design and construction of more than a dozen modern pharmaceutical plants in Europe and Russia.
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |